TrumpLyftAlles | 2 points
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness (Bangladesh 2020-12-02) IVM cleared covid faster but not other symptomhttps://ijidonline.com/article/S1201-9712(20)32506-6/fulltext
[-] TrumpLyftAlles | 1 points
[-] TrumpLyftAlles | 1 points
This study was briefly discussed in This Week in Virology, episode 691, starting at 1:32., also on youtube without the show notes.
This is one of the weakest ivermectin trials, and unfortunately it's the one that TWiV selected to discuss.
I really despise conspiracy theories -- but it does seem remarkable to me that Vincent picked out this one randomly. I wonder if he asked someone who has been following the research for an unimpressive study.
The only thing I learned (if Vincent is correct) is that doses used in US trials have to be approved, based on a dosing study showing that the dosing is safe. This trial did 12mg for 5 consecutive days. That is not FDA approved as treatment for anything, hence the need for a prior dosing study.
Three months ago Kyle Wagstaff said via LinkedIn that she is working on an ivermectin dosing study using human cells, and her findings to date make her unconcerned about the dose required, which (of course) is the first thing Vincent brought up.
Where is her dosing study? In that LinkedIn conversation, she said that she very much believes in the peer review process, so that's probably holding up publications, esp. since it's difficult finding enough reviewers these days, because of the onslaught of papers to review.
[-] MacroTurtleLibido | 2 points | Dec 12 2020 02:58:30
Actually, the study does show faster clinical clearance in the IVM group.
A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo (P=0.005) thus indicating early intervention with such an agent may limit viral replication within the host. In the 5-day ivermectin group there was significant drop of CRP and LDH by day-7 which are indicators of disease severity.
It is noteworthy that the viral nucleic acid cycle threshold value (indicator of viral load) significantly dropped compared to the placebo group on day-7 and day-14. In the absence of co-morbidity, a 5-day course of ivermectin treatment showed faster SARS-CoV-2 virus clearance compared to the placebo arm (9 vs.13 days; P = 0.02).
But I also really like the significant drop in the CT values indicating a faster clearance of viral load which, as we all know, is correlated with clinical, severity.
Still, overall a too small study that is underpowered. We need bigger trials!
permalink